Sequential GLP-1 Agonist and DPP-4 Inhibitor Therapy for Weight Maintenance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for type 2 diabetes and obesity often fail to achieve long-term glycemic control, are associated with weight gain, and have limitations in efficacy and tolerability, particularly in obese or overweight patients, who also face challenges in maintaining weight loss and preventing rebound weight gain after treatment cessation.
Innovation Solution
The sequential or combined use of a GLP-1 receptor agonist followed by a DPP-4 inhibitor, such as linagliptin, to induce weight loss and maintain reduced body weight, or to prevent weight gain, offering a therapeutic approach that addresses the limitations of existing treatments by improving glycemic control and reducing body fat.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for type 2 diabetes and obesity are used, then glycemic control is achieved, but weight gain occurs and long-term control is difficult to maintain
Solution Approach 1:
The patent combines two different therapeutic agents (GLP-1 receptor agonist and DPP-4 inhibitor) into a sequential treatment regimen. The GLP-1 receptor agonist is administered first to induce weight loss and improve glycemic control, followed by a DPP-4 inhibitor to maintain the achieved weight loss and sustain glycemic control, thereby resolving the contradiction between achieving glycemic control and avoiding weight gain
Solution Approach 2:
The treatment protocol employs preliminary action by first administering the GLP-1 receptor agonist to achieve initial weight loss and glycemic improvement before transitioning to the DPP-4 inhibitor. This preliminary phase creates a favorable baseline that enables long-term maintenance of both weight control and glycemic stability
2Weight of moving object
If weight loss treatment is administered to obese patients, then body weight is reduced, but rebound weight gain occurs after treatment cessation
Solution Approach 1:
The patent ensures continuity of useful action by transitioning from the GLP-1 receptor agonist to the DPP-4 inhibitor without treatment interruption. The DPP-4 inhibitor continues the weight management benefit after the initial weight loss phase, preventing rebound weight gain and extending the duration of weight loss maintenance
Solution Approach 2:
The treatment protocol changes therapeutic parameters by switching from a GLP-1 receptor agonist to a DPP-4 inhibitor. This parameter change allows the body to adapt to a new therapeutic mechanism that sustains weight loss effects and prevents rebound, thereby extending the duration of beneficial action
3Reliability
If existing diabetes and obesity treatments are used, then some therapeutic effect is achieved, but tolerability and safety are compromised
Solution Approach 1:
The patent employs a sequential treatment approach where the GLP-1 receptor agonist is used for a limited initial period to achieve weight loss, then discontinued in favor of the DPP-4 inhibitor for long-term maintenance. This disposable use of the GLP-1 agonist minimizes exposure to its side effects while still achieving therapeutic benefits, thereby improving overall tolerability
Data Source
Figure 1
Figure 2~3
Figure 4
AI summary
The present invention relates to methods for treating and/or preventing metabolic diseases comprising the combined administration of a GLP-1 receptor agonist and a DPP-4 inhibitor.